Index
The $149 rate on this page is not open-ended. The $149 rate covers 1.5 mg and 4 mg. The 4 mg price rises to $199 after this date. It stops applying on 2026-08-31, in 28 days.
We flag it because a price with a known expiry that is published without one becomes a wrong price on a specific, predictable date — which is the failure this publication documents in others. Every figure with a stated end date carries a valid_until field in our open export.
The Library: Every Guide, Study and Analysis
Every long-form page on this site in one index: guides, comparison fields, medications, analysis, clinical trials, news, provider records and tools. It is generated from the…
Every long-form page on this site in one index: guides, comparison fields, medications, analysis, clinical trials, news, provider records and tools. It is generated from the rendered site, so a page cannot be published without appearing here.
Section hubs list their own section. This lists everything, because more than half the writing on this site previously had no index it appeared in.
286 long-form pages, 615,100 words, generated from the rendered site on 2026-08-03. Nothing is listed here by hand.
Guides (129)
Comparison fields (5)
| Page | Words | Updated |
|---|---|---|
| Which The active ingredient Providers Have Flat Pricing, and Which Charge More at Higher Doses | 1,586 | 2026-08-03 |
| Which The molecule Providers Charge a Separate Membership Fee | 1,091 | 2026-08-03 |
| Which This GLP-1 Provider Prices Have Actually Been Verified | 4,249 | 2026-08-03 |
| What Is Actually Included in a The approved product Telehealth Price | 1,080 | 2026-08-03 |
| Tirzepatide Provider Clinical Models: Continuity, Response Times and Whether Labs Are Included | 1,177 | 2026-08-03 |
Medications (1)
| Page | Words | Updated |
|---|---|---|
| Semaglutide Providers Compared: Every Route, With Its Evidence | 1,491 | 2026-08-03 |
Analysis (27)
Research (22)
News (52)
Provider records (23)
Pharmacies (10)
| Page | Words | Updated |
|---|---|---|
| What PCAB Accreditation Means | 1,191 | 2026-08-03 |
| USP 797 Sterile Compounding, Explained | 1,196 | 2026-08-03 |
| State Board Pharmacy License Check Guide | 1,403 | 2026-08-03 |
| How to Verify a Compounding Pharmacy | 1,628 | 2026-08-03 |
| How to Use NABP Safe Pharmacy Resources | 1,152 | 2026-08-03 |
| Compounding Pharmacy Recalls and Warning Letters | 1,735 | 2026-08-03 |
| Cold-Chain Shipping for Compounded GLP-1s | 1,227 | 2026-08-03 |
| Certificates of Analysis and Third-Party Testing | 1,228 | 2026-08-03 |
| 503B Outsourcing Facility Directory | 1,747 | 2026-08-03 |
| 503A Compounding Pharmacy Directory | 1,264 | 2026-08-03 |
Peptides (6)
| Page | Words | Updated |
|---|---|---|
| Tesamorelin: The Peptide That Actually Has an Approval and a Trial Programme | 2,025 | 2026-08-03 |
| TB-500: Thymosin Beta-4, Animal Data, and a Regulatory Decision in Progress | 2,433 | 2026-08-03 |
| Sermorelin: A Growth-Hormone Secretagogue With a Narrow Approved History | 2,073 | 2026-08-03 |
| NAD+ Therapy: Strong Biology, Weak Clinical Evidence | 1,831 | 2026-08-03 |
| CJC-1295 and Ipamorelin: A Popular Stack With No Approved Product Behind It | 2,430 | 2026-08-03 |
| BPC-157: The Evidence, the Regulatory Position, and Why the Two Diverge | 2,303 | 2026-08-03 |
Tools (11)
| Page | Words | Updated |
|---|---|---|
| Weight-Loss Percentage Calculator | 996 | 2026-08-03 |
| Tirzepatide State Availability Finder | 812 | 2026-08-03 |
| Tirzepatide Clinical Trial Finder | 990 | 2026-08-03 |
| Questions to Ask a GLP-1 Clinician | 846 | 2026-08-03 |
| Provider Match: Ten Questions, Then What the Evidence Supports | 1,325 | 2026-08-03 |
| GLP-1 Total Cost Calculator | 883 | 2026-08-03 |
| GLP-1 Semaglutide Rx Tool | 2,847 | 2026-08-03 |
| GLP-1 Hidden Fee Calculator | 834 | 2026-08-03 |
| Compounding Pharmacy Verification Tool | 1,029 | 2026-08-03 |
| BMI Calculator | 984 | 2026-08-03 |
| Annual GLP-1 Cost Calculator | 811 | 2026-08-03 |
Frequently asked questions
Where can I find every article on this site?
This page. It is generated from the rendered site rather than maintained by hand, so a page cannot be published without appearing in it.
How is it ordered?
Grouped by section, then by the date the page was last updated, newest first. Word counts are measured from the rendered body, excluding navigation and footers.
Related on this site
- How we score providersCore & Trust
- Work out your all-in costTools
- Pricing data, CSV and JSONData
- Tirzepatide, Lean Mass and Muscle LossResearch
- Tirzepatide vs Semaglutide: What the Head-to-Head Trial ShowsJournal
- Tirzepatide and Type 2 Diabetes PreventionResearch
- Tirzepatide and PCOS: What Evidence Exists?Research
- Tirzepatide and Fatty Liver / MASHResearch
- Tirzepatide and Chronic Kidney DiseaseResearch
- Tirzepatide and Cardiovascular OutcomesResearch
Related coverage
- Cheapest tirzepatide, answered six ways
- What you pay at a maintenance dose
- GLP-1s and Bone: What Rapid Weight Loss Does to a Skeleton
- GLP-1s and the Gallbladder: Rapid Weight Loss Is the Risk Factor
- GLP-1s and Gastroparesis: Where Intended Effect Ends and Diagnosis Begins
- GLP-1s and the Kidneys: Demonstrated Benefit and a Dehydration Route to Harm
- GLP-1s and Mental Health: What the Regulatory Reviews Concluded
- GLP-1s and Pregnancy: Not Recommended, and the Planning That Follows
- GLP-1s Before Surgery: Why Anaesthetists Care About Delayed Gastric Emptying
GLP-1 Semaglutide Rx. “The Library: Every Guide, Study and Analysis.” S.J Partners LLC, 2026-08-03. https://glp1semaglutiderx.com/library/
Quote the capture date beside a figure, not the date you read this page. Why.
Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.